New Drug Reviews
Vemurafenib in Patients With BRAF V600E Mutation–Positive Advanced Melanoma
Vemurafenib is an oral, small-molecule kinase inhibitor that selectively targets activated BRAF V600E and has been approved for the treatment of advanced BRAF mutation–positive melanoma.
